<b>Background/Objectives</b>: The emergence of FLT3 inhibitors (FLT3i) has radically transformed the prognostic and therapeutic landscape for FLT3-mutated Acute Myeloid Leukemia, stimulating the need for comprehensive and structured clinical guidance. The gene discussed is FLT3; the disease is acute myeloid leukemia.